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Methods: A	 survey	 questionnaire	 was	 circulated	 electronically	 to	 members	 of	















Conclusions and Inferences: These data highlight the difficulties with diagnosing and 
managing	CIPO	and	ED	and	underscore	the	urgent	need	for	international,	multidisci-
plinary,	clinical	practice	guidelines.
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1  | INTRODUC TION
Recent international studies have confirmed that small intestinal mo-
tility disorders represent a common cause of chronic intestinal fail-
ure	requiring	long-term	parenteral	feeding,	accounting	for	up	to	18%	
of	 adult	 patients	 requiring	 long-term	 parenteral	 nutrition	 (PN).1,2 
Moreover,	in	recent	years,	it	has	been	suggested	that	there	may	be	
an upward trend in the number of newly diagnosed patients with 
motility	disorders	 requiring	 long-term	PN.3,4	Despite	 this	 increase,	
in the absence of universally agreed national or international guide-




Based	 on	 findings	 from	 radiological	 and	motility	 tests,	 small	
intestinal dysmotility can be sub-classified into chronic intestinal 
pseudo-obstruction	(CIPO)	and	enteric	dysmotility	(ED).6-10	CIPO	
is defined as chronic/recurrent obstructive type symptoms with 
radiological features of dilated intestine with air/fluid levels in the 
absence of any lumen-occluding lesion.7,9	By	contrast,	ED	refers	to	
patients with objective evidence of small bowel dysmotility on an-
troduodenal	manometry	(ADM),	but	without	radiological	features	
of a dilated intestine.10,11 There is some evidence that outcomes 
are	 significantly	 worse	 in	 patients	 with	 CIPO	 compared	 to	 ED,	
with	 a	higher	 requirement	 for	 long-term	PN	dependency,	 higher	
mortality,	 and	 complications	 including	 small	 intestinal	 bacterial	
overgrowth and the need for surgical interventions.6,12	However,	
there remains considerable debate among clinicians on the merits 
of	 sub-classifying	 small	 intestinal	 dysmotility	 into	CIPO	 and	 ED.	
The	debate	predominantly	relates	to	the	limitations	of	ADM	as	a	
diagnostic	test,	due	to	its	invasiveness,	which	often	results	in	poor	
tolerance,	 variability	 in	 results,	 poor	 correlation	with	 symptoms	
and	histopathology,	 apparent	 limited	 impact	on	patient	manage-
ment,	and	 lack	of	availability.5,7,11,13,14	Another	contentious	 issue	
in the diagnosis and classification is the role of full thickness bi-
opsies.	While	patients	with	small	intestinal	dysmotility	have	been	
shown to have a high incidence of gastrointestinal neuromuscular 
disorders	 (GINMD),12,15 the diagnostic utility and the risk: bene-
fit ratio of performing a full thickness small bowel biopsy remains 
unclear,8 despite publication of international consensus guidelines 
for histopathological diagnosis of GINMD.16,17
Therefore,	 in	 the	 absence	 of	 well-defined	 national	 or	 interna-
tional	clinical	practice	guidelines,	we	hypothesized	that	there	would	
be a variation in opinions and clinical practice between experts 
across	Europe	in	diagnosing	and	managing	CIPO	and	ED.
The aim of this survey was therefore to evaluate current opinions 
on	the	diagnosis	and	management	of	CIPO	and	ED	among	interna-
tional clinical practitioners.
2  | MATERIAL S AND METHODS
2.1 | Questionnaire structure
A	 thirty-nine	 item	 questionnaire	 evaluating	 clinical	 practice	 and	
opinions	on	 the	diagnosis	 and	management	of	CIPO	and	ED	was	
developed	 by	 the	 Home	 Artificial	 Nutrition	 &	 Chronic	 Intestinal	
Failure	 specialist	 interest	 group	 of	 the	 European	 society	 for	
Clinical	 Nutrition	 and	 Metabolism	 (ESPEN),	 in	 conjunction	 with	
representatives	 from,	 the	 British	 Society	 of	 Gastroenterology	







cialist	 interest	 group,	 the	 study	questionnaire	was	 structured	 into	
the following subsection surveys:
1.	 respondent's	 clinical	 background,	 sub-speciality,	 nationality,	 in-













• The majority of expert clinicians believe that chronic in-
testinal	pseudo-obstruction	(CIPO)	and	enteric	dysmo-
tility	(ED)	should	be	recognized	separately.
• Clinicians find making the diagnosis of ED particularly 
challenging due to current limitations of diagnostic tests 
for	 small	 intestinal	 dysmotility,	 often	 resulting	 in	 de-
layed diagnoses.
• Current best management is multidisciplinary with gut-
brain	 neuromodulators,	 treatment	 of	 bacterial	 over-
growth,	 prokinetics,	 clinical	 psychology,	 with	 careful	
nutritional assessment and support.
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This study was designed to survey the practices and opinions 
of	clinicians	with	an	 interest	 in	CIPO	and	ED,	primarily	 targeting	
those in advanced clinical nutrition roles/intestinal failure teams 
or luminal gastroenterologists with a sub-speciality interest in 
neurogastroenterology	 and	 motility.	 Participants	 were	 provided	





cific	 set	 of	 questions	 only	 applicable	 to	 participants	working	 in	 a	
chronic intestinal failure setting with significant experience in long-
term	PN	management	and	intestinal	transplant	referrals.	Therefore,	
those without intestinal failure experience were automatically di-
rected	to	the	end	of	the	questionnaire	by	the	online	survey	software	
on completion of section 4. Only responses from participants work-
ing in centers with >20	patients	on	long-term	PN18 were included in 
the analyses for section 5.








An	 invitation	 to	participate	with	a	weblink	 to	 the	questionnaire	
created by the survey software was circulated electronically via 
newsletters published for members of the following international 
societies;	ESPEN,	ESNM,	and	United	European	Gastroenterology.	
Clinicians identified by the international study team who 
have an interest and expertise in GID were also invited to par-
ticipate	 in	 the	 survey	 via	 email.	 Survey	 data	 were	 collected	




Survey	 data	 were	 analyzed	 using	 counts	 and	 proportions.	




Overall,	 154	 participants,	 (UK	 40%,	 Europe	 43%,	 and	 Non-European	
Countries	17%)	completed	sufficient	questions	to	be	included	in	the	study.
Most	responders	were	gastroenterologists	(66%),	a	further	16%	
were	 sub-specialists	 in	 neurogastroenterology	 and	 motility,	 12%	
were	 gastrointestinal	 surgeons,	 and	 6%	were	 intestinal	 transplant	
clinicians.	Overall,	56%	had	a	sub-specialty	interest	in	intestinal	fail-
ure	 and	85%	were	 consultants/attending	 clinicians	 or	 clinical	 aca-
demics/ professors.




≤10	new	 referrals	with	 suspected	or	 confirmed	CIPO	and	ED	per	





a recent change in the proportion of small intestinal dysmotility re-
ferrals	with	CIPO	and	ED.	More	than	half	 (51%)	reported	observing	




TA B L E  2  Clinicians'	estimate	of	time	between	symptom	onset	to	
GID diagnosis
Average time to reach 
diagnosis
CIPO diagnosis
n = 154 (%)
ED diagnosis
n = 154 (%)
<6 mo 14	(9) 10	(6)
6-12 mo 45	(29) 24	(16)
1-5 y 70	(45) 91	(59)
5-10 y 23	(15) 25	(16)
>10 y 2	(1) 4	(3)
TA B L E  1  Clinicians'	estimate	of	the	percentage	of	new	referrals	
with small bowel dysmotility that meet clinical radiological criteria 
for	CIPO	(n	=	154)
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secondary cause for dysmotility is found in fewer than half of cases. 
When	reviewing	a	list	of	secondary	causes	of	CIPO	and	ED,	they	re-




3.3 | Participant's practice and opinions on 
diagnostic approaches in suspected CIPO/ED
Most	participants	agreed	 that	CIPO/ED	diagnoses	are	difficult	 to	
make,	and	only	5%	 found	 them	straightforward.	 In	particular,	 the	
majority	of	participants	(56%)	found	ED	to	be	a	difficult	diagnosis,	
while	only	10%	reported	that	CIPO	is	a	more	difficult	diagnosis.	The	
reasons	 that	participants	most	 frequently	 selected	 for	difficulties	
and diagnostic delays in >50%	of	cases	included	non-specific	symp-
toms	 (70%),	 lack	of	awareness	of	CIPO/ED	among	non-specialists	











5/131	(4%),	P > .99; only when specimens available from previous or 
planned	surgery	8/22	(36%)	vs	42/131	(32%),	P = .81; and when the 
diagnosis	is	unclear	9/22	(41%)	vs	57/131	(44%),	P >	.99).
The general consensus among participants was that full thickness 




especially when it came to opinions on their role in determining the 
prognosis	and	choice	of	prokinetic	treatment	(Table	4).
3.4 | Opinions on the efficacy of various 
management options for CIPO and ED
While	very	few	options	appear	to	benefit	the	majority	of	cases,	cli-
nicians reported that the most effective options were neuropathic 
analgesia,	 antibiotics	 for	 small	 intestinal	 bacterial	 overgrowth,	
F I G U R E  1  Summary	of	motility	investigations	requested	by	participants	in	suspected	CIPO	and	ED
TA B L E  3  Changes	in	the	frequency	of	secondary	causes	of	
CIPO/ED
Associated conditions
% reporting increase 
















     |  5 of 9VASANT eT Al.
prucalopride,	 and	 clinical	 psychology	 (Table	 5).	 Participants	 re-
ported	psychological	 co-morbidity	 in	patients	with	CIPO	and	ED.	
Patients	 with	 ED	 were	 reported	 to	 exhibit	 more	 psychological	
co-morbidity	 according	 to	 56%	 of	 respondents	 than	 those	 with	
CIPO.	Only	9%	 felt	 that	patients	with	CIPO	have	more	prevalent	




opined that ED patients have a higher readmission rate than those 
with	CIPO,	while	28%	believed	 that	patients	with	CIPO	are	more	
likely to be readmitted.
Interestingly,	52%	of	those	surveyed	reported	that	they	have	re-









3.5 | Survey of clinical experience and practice with 
long-term PN in CIPO and ED related chronic (type 3) 
Intestinal Failure
A	total	of	59	participants	work	 in	units	with	≥20	patients	on	 long-














Domperidone 15 43 29 13
Metoclopromide 10 45 29 10
Erythromycin 13 44 30 11
Prucalopride 19 31 30 18
Linaclotide 34 34 21 9
Octreotide 38 41 15 5
Neostigmine/
Pyridostigmine
31 44 16 7
Cisapride 66 15 13 5
Naloxegol 43 37 15 5
Antibiotics	for	
SIBO
2 22 41 27
Neuropathic 
analgesics
10 29 43 15
Opiates 52 35 13 0
Venting 
gastrostomy
13 55 22 8
Venting colostomy 48 39 8 4
Enteral feeding 9 43 36 10
Parenteral	
nutrition
5 36 36 19
Psychology 13 29 30 22
Surgery 20 66 12 3


















23% 59% 14% 5% 0
Other 
clinicians
11% 40% 17% 13% 19%
Fisher's	exact	
test,	P values




36% 41% 18% 5% 0
Other 
clinicians
21% 33% 18% 18% 11%
Fisher's	exact	
test,	P values




27% 45% 14% 14% 0
Other 
clinicians
16% 28% 18% 25% 13%
Fisher's	exact	
test,	P values
.23 .12 .69 .25
Influence choice of prokinetics
NGM 
clinicians
59% 27% 5% 9% 0
Other 
clinicians
20% 34% 11% 18% 14%
Fisher's	exact	
test,	P values




18% 45% 23% 14% 0
Other 
clinicians
7% 24% 25% 31% 14%
Fisher's	exact	
test,	P values
.12 .04 .83 .10
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cases	according	to	1	respondent.	Interestingly,	36	of	the	59	clinicians	
managing	long-term	PN	reported	that	1%-10%	of	their	long-term	PN	
population have suspected small bowel dysmotility without meet-






tom benefit in >50%	of	cases	(Table	6).	Moreover,	it	was	the	opinion	













reported that catheter complication rates are similar to other causes 
of	intestinal	failure.	Intestinal	failure-associated	liver	disease	(IFALD)	
rates were reported to be similar to other causes of intestinal failure 
by	73%	of	clinicians.	The	vast	majority	of	 respondents	 (86%)	 indi-
cated that ED has a higher psychological co-morbidity than other 









in making intestinal transplant referrals for patients with chronic in-
testinal	failure.	Of	these	participants	with	experience,	the	majority	
(76%)	reported	that	they	would	refer	patients	with	both	CIPO	and	




This is the first large-scale survey on the diagnosis and management 
of	CIPO	and	ED	and	confirms	that	 there	 is	currently	a	wide	varia-
tion in clinical practice internationally. These data also identify that 
diagnostic	delays	are	reported	to	be	common	in	CIPO	and	ED	and	
provide some important insights into the difficulties currently faced 
by	clinicians	investigating	and	managing	these	patients,	which	could	











Dehydration 1	(2) 19	(33) 11	(19) 26	(46) 2
Metabolic impairments 2	(4) 18	(32) 14	(25) 23	(40) 2
Quality-of-life 4	(7) 16	(28) 13	(23) 24	(42) 2
Bacterial translocation 29	(51) 21	(37) 6	(11) 1	(2) 2
Gastrointestinal symptoms 6	(11) 22	(39) 15	(27) 13	(23) 3
Aspiration	pneumonia 18	(32) 26	(46) 5	(9) 7	(13) 3
Hospital admissions 5	(9) 22	(39) 14	(25) 16	(28) 2
TA B L E  6   Clinical opinions on the utility 
of	HPN	in	CIPO	and	ED	related	intestinal	














8	(14) 15	(27) 15	(27) 18	(32) 3
Full	thickness	biopsy	
result
12	(21) 17	(30) 10	(18) 17	(30) 3
Tolerance of oral or 
enteral intake
0	(0) 5	(9) 10	(18) 42	(74) 2
Manometry findings 23	(41) 24	(43) 5	(9) 4	(7) 3
Age	at	diagnosis 6	(11) 27	(47) 10	(18) 14	(25) 2
Long-term	opiate	use 0	(0) 12	(21) 12	(21) 33	(58) 2
Psychological	factors 0	(0) 7	(12) 17	(29) 34	(58) 1
TA B L E  7   Opinions on predictive 
factors	for	long-term	PN	dependency	in	
CIPO/ED
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survey also provides information for the first time on the perceived 




ing	CIPO	 as	 a	 separate	 clinical	 entity,	 and	 this	would	 be	 consis-
tent	with	clinical	data	which	have	shown	that	the	CIPO	sub-type	
is associated with a significantly worse prognosis.6,12 The trends 








ations between functional gastrointestinal disorders and hyper-
mobile	 Ehlers-Danlos	 are	 increasingly	 recognized,19 and recent 
data	from	a	UK	population	have	shown	a	very	high	prevalence	of	
functional gastrointestinal disorders in patients with hypermobile 
Ehlers-Danlos	syndrome,	with	84%	meeting	the	diagnostic	criteria	
for functional disorders in multiple gut regions.20 The reasons for 
this	 trend	being	specific	 to	UK	participants	are	unclear,	but	may	
stem from an awareness being higher due to most of the stud-
ies	 to	 date	 emanating	 from	 the	UK.	 It	would	 seem	unlikely	 that	
increased	 awareness	 alone,	 however,	would	 drive	 an	 increase	 in	
severe	clinical	presentations	requiring	nutrition	support.	Further	
international collaborative epidemiological research on the preva-













even when referring patients with suspected functional and motility 
disorders for parenteral feeding.
The survey data therefore highlight the need for better diagnos-
tic	tests	for	ED.	There	are	a	number	of	promising	techniques	includ-
ing wireless motility capsule21,22 and Cine MRI23-25 which are being 
evaluated	and	are	available	in	some	centers,	but	were	only	routinely	
available	 for	 16%-17%	 of	 respondents	 in	 this	 survey.	However,	 in	
the	interim,	as	proposed	by	Paine	et	al,	a	more	pragmatic	approach	
to diagnosing severe gastrointestinal dysmotility can be adopted.8 
This	approach	would	not	mandate	ADM	for	an	ED	diagnosis.	Instead,	
this pragmatic approach takes into consideration those with sug-





Diagnostic	 delays	 appear	 to	 be	 fairly	 common	 in	 CIPO	 and	
ED.12,26 The survey data suggest a lack of awareness of this 
group of disorders among non-specialists. This is clearly import-
ant as diagnostic delays and lack of knowledge may explain the 
high incidence of inappropriate surgical interventions that have 
not	only	been	identified	in	this	survey,	but	also	in	several	clinical	
studies.12,14,27 Delayed diagnosis may also significantly impact the 
patients'	psychological	well-being	28 and have been shown in other 
functional gastrointestinal disorders to be associated with stigma-
tization.29	Therefore,	 there	 is	a	clear	need	 to	 raise	awareness	of	
CIPO	and	ED	with	appropriate	educational	strategies	among	the	
wider clinical community including gastroenterologists and associ-
ated specialists such as surgeons and dieticians in order to prevent 
diagnostic	 delays,	 potentially	 hazardous	 surgical	 interventions,	
and improve clinical outcomes.
In	addition	 to	difficulty	with	diagnosis,	 respondents	also	 further	
highlighted the lack of efficacy of many of the established therapies 
for	CIPO	and	ED.	Strategies	which	ranked	best	included	treatment	of	
bacterial	overgrowth,	clinical	psychology,	 the	pan-enteric	prokinetic	
prucalopride,	PN,	 and	neuropathic	 analgesia.	When	considering	 the	
latter,	 it	 is	noteworthy	 that	patients	with	ED	 in	particular	often	ex-
hibit	 severe	 neuropathic/centrally	 mediated	 abdominal	 pain,	 which	
responds very poorly to opioids. Indeed opioids can be detrimental in 
this	setting	due	to	their	antimotility	effects,	worsen	pain	due	opioid	in-
duced	hyperalgesia,30	and	potentially	increase	infection	risk,31 which 
is	 particularly	 important	when	 considering	HPN.32 The current sur-
vey data are thus in accordance with an increasing body of evidence33 
and recently published clinical guidelines to support use of centrally 
acting gut-brain neuromodulators rather than the standard use of opi-
oid medications to target this type of neuropathic pain.34,35	Notably,	
respondents highlighted the importance of the multidisciplinary care 
including	clinical	psychology.	Since	no	single	treatment	was	reported	
to	be	highly	efficacious,	it	is	vital	that	care	is	holistic	and	that	the	psy-







dence	 and	 management,	 rather	 than	 provide	 actual	 figures	 from	
their	clinical	practice.	Another	limitation	of	the	study	is	that	partic-
ipants were not asked to report separately on the efficacy of all the 
specific treatments between sub-types. It is therefore not possible 
to determine whether there were any perceived differences in the 
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and	some	effect	on	quality	of	life	in	many	patients.	However,	PN	was	






with the majority of those surveyed reporting either similar or better 
survival outcomes compared to other causes of intestinal failure. The 
experiences of the survey participants are consistent with published 





from a large number of international experts in small bowel dysmotil-
ity. The data have demonstrated that in the absence of clear clinical 
guidelines,	diagnosis	and	management	of	CIPO	and	ED	is	challeng-
ing,	with	a	wide	variation	in	practice.	The	data	suggest	clinical	man-
agement of these conditions should be multidisciplinary including 
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